Guggenheim Downgrades Globant Stock Rating Due to Weak Bookings
Guggenheim revised its rating for Globant stock downward, citing weak booking performance. The analyst firm's decision points to a slowdown in the company's booking flow.
The downgrade may lead investors to reassess their expectations regarding Globant's growth outlook. Weakness in bookings stands out as a signal that puts pressure on revenue projections for the upcoming period.
Guggenheim's decision reflects increasing sensitivity to demand conditions in the technology and software services sector. The firm's assessment is based on the loss of momentum in Globant's order volume.
Not investment advice.
📊 GLOB — Piyasa Yorumu
▼ down · 60%Guggenheim's downgrade points to weak bookings, creating a negative catalyst in the short term. Technical indicators are mixed: RSI at 60 is not near overbought territory, MACD is positive above its signal line, and the price is trading above SMA20/SMA50. However, downgrade news typically creates selling pressure in the first few days, and there is a possibility of a pullback from the 48.82 level. Nevertheless, the strong technical base suggests the decline may remain limited. I expect downward pressure in the short term, but additional confirmation is needed for a sharp drop.
RSI 14
60.2
MACD
0.29
24h Δ
-0.30%
Canlı Grafikler
🔗 İlgili haberler
⭐ 67 · 21.04
3 Ders Amazon’un Blockbuster Anlaşmasından Globalstar Satın Alma Sürecine
⭐ 63 · 18.04
Amazon’ın 12 Milyar Dolarlık Globalstar Satın Alımı Bir Günde 10 Kat Artarak Kendi Kendini Ödeyebildi
⭐ 76 · 17.04
Starlink Rakibi Globalstar, Amazon Anlaşmasıyla Hızlandı
⭐ 63 · 09.04
Globant S.A. (GLOB), Artan Yapay Zeka Bozulması Endişeleriyle Düşüş Gösterdi
⭐ 65 · 09.04
Kolombiya Emeklilik Fonlarına Yurtdışı Varlık Üst Sınırı Getirdi
🧬 Buna benzer
⭐ 68
Guggenheim, DraftKings Hedef Fiyatını 35 Dolara İndirdi
⭐ 68
AbbVie hissesi 245,26 dolar ile tüm zamanların en yüksek seviyesine ulaştı
⭐ 63
HPE'nin İkinci Çeyrek Karlılığı Beklentileri Geride Bıraktı, Hisse Değer Kazandı
⭐ 68
AbbVie’nin yumurtalık kanseri ilacı denemede %62,7 yanıt oranı gösterdi
AI tarafından yeniden derlenmiştir. Yatırım tavsiyesi değildir.